Clinical trials: active, sponsored by University of Manchester
Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction
Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction).
- Conditions
- Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Left Ventricular Outflow Tract Obstruction, Myocardial Ischaemia
- Trial name
- PEACH (NCT07120776)
- Testing
- Camzyos (Mavacamten)
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Manchester
Rare Disease, Undiagnosed Disease
EpiSign International: Expanding Epigenomic Testing in Rare Disease
The purpose of this study is to assess the utility of EpiSign software and an integrated DNA methylation and copy number variant (CNV) microarray technology in helping to diagnose individuals with rare diseases.
- Conditions
- Rare Disease, Undiagnosed Disease, Genetic Diseases, Inborn, Congenital Abnormalities
- Trial name
- NCT07839754
- Testing
- Integrated EPIC/CNV microarray with EpiSign analysis, EpiSign analysis with EPIC DNA methylation microarray
- Where
- United Kingdom
- Volunteers
- 192 people
- Sponsor
- University of Manchester
Psychosis, Schizophrenia Spectrum Disorders
A Case Series of Culturally-adapted CBTp for Black People in the UK
The goal of this case series study is to learn if culturally-adapted cognitive-behavioural therapy is practical, acceptable and safe among Black Sub-Saharan African and Caribbean people experiencing psychosis.
- Trial name
- NCT07252206
- Testing
- Culturally-adapted cognitive-behavioural therapy
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Manchester
Pediatric Cancer
Granulocyte Transfusions After Umbilical Cord Blood Transplant
Although most children with leukaemia are cured using drugs (chemotherapy) alone, for some children additional treatments are needed. Stem cell transplant can cure children where chemotherapy and other drugs have failed.
- Trial name
- NCT05425043
- Testing
- Granulocytes
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Manchester
Cancer
MR-BIO: A Study to Evaluate Changes in MR Imaging and Biological Parameters
The MR BIO study aims to understand the changes in the tumour and normal tissues during a course of radiotherapy. This is accomplished by studying the MR images taken during each treatment session on the MR Linear accelerator (MR…
- Trial name
- MR-BIO (NCT04903236)
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer
Selecting Hypoxic Tumours for Treatment Modification
Approximately 50% of cancer patients with solid tumours will be treated with radiotherapy. A significant proportion (>25%) of patients have hypoxic tumours which respond poorly to radiotherapy.
- Trial name
- SELECT (NCT06787053)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Manchester
Cervical Cancer
Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer
Patients with locally advanced cervical cancer (LACC) are primarily treated with radiotherapy +/- chemotherapy however 5-year survival rates are <60% with significant treatment toxicity.
- Trial name
- Bio-CHECC (NCT05029258)
- Testing
- Biopsy of tumour, MRI scans
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Chondral Defect
The Biomechanical Outcomes of Autologous Chondrocyte Implantation
Injury to the knee can damage the lining of the knee's bones, called cartilage. Cartilage injuries cause pain and limit movement, making activities like walking, playing sports, and working difficult.
- Trial name
- NCT06921889
- Testing
- Autologous Chondrocyte Implantation (ACI)
- Where
- 7 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- University of Manchester
Hypertrophic Cardiomyopathy (HCM)
Multicentre Hypertrophic Cardiomyopathy Registry
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow…
- Trial name
- NCT07381894
- Where
- United Kingdom
- Volunteers
- 2,500 people
- Sponsor
- University of Manchester
Maternal Cardiometabolic Health, Infertility
St Mary's Assisted Reproductive Technology and Cardiometabolic Health: Modifiable Targets for Multimorbidity Prevention (START-HEALThY)
The main causes of death in women are conditions affecting the heart and blood vessels (cardiovascular disease, CVD). Women who have difficulties getting pregnant (infertility) may be at increased risk, but the reasons for this…
- Conditions
- Maternal Cardiometabolic Health, Infertility, Assisted Reproductive Technology, Cardiovascular Health
- Trial name
- START-HEALThY (NCT07173569)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Patient Safety Concerns
Using IF-THEN Plans to Support Healthcare Professionals in Raising Patient Safety Concerns
This study aims to test whether a brief behavioural intervention can help healthcare professionals raise and respond to patient safety concerns in their work.
- Trial name
- NCT07506096
- Testing
- Implementation intention planning
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Stillbirth, Perinatal Death
A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experienced a Perinatal Death
The goal of this feasibility randomised control trial is to determine if a trial to evaluate perinatal bereavement counselling for parents who have experienced a perinatal death is feasible.
- Conditions
- Stillbirth, Perinatal Death, Psychological, Grief
- Trial name
- PEARL-C (NCT07494760)
- Testing
- Bereavement Counselling, Usual bereavement care
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Mucopolysaccharidosis II
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II
MPS II is a genetic disorder that affects boys. Boys with MPS II are missing a working enzyme known as iduronate-2-sulfatase (IDS) which is needed to break down long sugar chains in the body.
- Trial name
- NCT05665166
- Testing
- Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- University of Manchester
Patient Safety Concerns
Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care
The aim of the present research is to test the effectiveness of an implementation intention-based intervention for promoting the raising of safety concerns by patients in healthcare settings.
- Trial name
- NCT07084090
- Testing
- Implementation intention planning
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Stillbirth
The Tommy's National Rainbow Clinic Study
The death of a baby before or shortly after birth affects approximately 1 in every 250 pregnancies in the UK meaning that over 4,000 parents experience the death of a baby each year in the UK.
- Trial name
- NCT04393259
- Testing
- Rainbow Clinic Model of Antenatal Care
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- University of Manchester
Acute Myeloid Leukemia, Stem Cell Transplantation
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
Allogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death.
- Conditions
- Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Cord Blood Stem Cell Transplantation
- Trial name
- GRACE (NCT07372885)
- Testing
- Cord blood transplantation + conditioning + granulocytes of variable days according to study design
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Manchester
Stillbirth and Fetal Death, Perinatal Death
Mothers Working to Prevent Early Stillbirth Study 20-28
This project aims to identify factors linked to pregnancy losses occurring between 20 and 28 weeks of pregnancy that can be modified by changing mother's behaviour or healthcare provision.
- Trial name
- MiNESS20-28 (NCT06005272)
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 948 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Hypertrophic Cardiomyopathy (HCM)
Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy
This research study, aims to understand why a specific heart medication called mavacamten works better for some people with hypertrophic cardiomyopathy (HCM) than for others. We believe the answer might be in our genes.
- Trial name
- PRO-Gene Mava (NCT07408427)
- Testing
- Observational study, no new intervention offered
- Where
- United Kingdom
- Volunteers
- 140 people
- Sponsor
- University of Manchester
Cardiovascular Diseases, Immune-Mediated Inflammatory Diseases
UK CARDIOvascular Immune-Mediated Inflammatory Diseases (CARDIO-IMID) Registry Study
The goal of this observational study is to develop a large, deeply characterised cohort that will be a platform for collaborative clinical and translational research into cardiovascular (CV) disease (CVD) and…
- Trial name
- CARDIO-IMID (NCT06478277)
- Where
- 2 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- University of Manchester
Hypertrophic Cardiomyopathy (HCM)
Myocardial Energetic Restoration in the Treatment of Obstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart condition, where the heart muscles can thicken to the point of obstructing blood flow out of the heart.
- Trial name
- MERIT HCM (NCT07332767)
- Volunteers
- 20 people
- Sponsor
- University of Manchester